Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. Eur Heart J. 2015;36(23):1470-7. 3 Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368(8):699-708. 4 Lanssen M,...
apixaban (Eliquis) edoxaban (Savaysa) betrixaban (Bevyxxa) These agents are associated with a higher risk of gastrointestinal bleeding. Explanation When DOACs are taken, especially for the first time, patients may be at risk of bleeding.
Apixaban (2.5 mg twice daily) versus VKA resulted in a significant reduction in life-threatening bleeding (3.5% vs. 5.3%; p < 0.01) and 30-day rate of stroke (2.1% vs. 5.3%; p = 0.17) (44). A retrospective analysis found no difference in terms of a composite endpoint of post-...
Andexanet alfa Apixaban EGEN-001 Edoxaban Enoxaparin Rivaroxaban treatment 1 completed NCT02557672 PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding Coagulation Factor IX Human Coagulation factor VII human Coagulation factor X human Factor IX Complex (Human) Protein C Protein S huma...
Patients were excluded if they met any of the following criteria: concomitant use of low-dose aspirin, use of antiplatelet agents other than aspirin, use of anticoagulants such as warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban, or any steroid; use of two or more NSAIDs; and use ...
(1.7% vs 1.3%, respectively; OR, 1.40; 95% CI, 1.15-1.70) were associated with increased odds of major GI bleeding compared with conventional anticoagulation, whereas no difference was found for apixaban (0.6% vs 0.7%, respectively; OR, 0.81; 95% CI, 0.64-1.02) or edoxaban (1.9% vs ...
Cancer patients have an increased risk of bleeding compared to non-cancer patients with anticoagulant therapy. A bleeding risk assessment before initiation
bilateral pupillary dilation or decerebrate posturing are indicators for an extreme risk of imminent death or irreversible brain damage. Given the extreme risk of death if no measures are undertaken, the risk–benefit balance seems favourable; however, it is important to normalise PaCO2as soon as ...
Daily doses of allowed OACs include apixaban 5 mg bid or apixaban 2.5 mg bid, if at least 2 among age ≥80 years, body weight ≤60 kg or serum creatinine level ≥1.5 mg/dL (or 133 mol/L); dabigatran 150 mg bid or 110 mg bid; edoxaban 60 mg or 30...
Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med, 365 (11) (2011), pp. 981-992 View in ScopusGoogle Scholar [36] R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, et al. Edoxaban versus warfarin in patients with atria...